Functionally selective dopamine D₂, D₃ receptor partial agonists.

Area of Science:

• Medicinal Chemistry
• Neuropharmacology
• Psychiatry

Background:

• Schizophrenia's negative symptoms are linked to dopamine D2 receptor (D2R) signaling bias.
• Targeting Gα(o) over Gα(i) signaling may offer a therapeutic strategy for schizophrenia.
• Developing selective D2R ligands is crucial for improved treatment outcomes.

Purpose of the Study:

• To synthesize and characterize novel heterocyclic dopamine surrogates based on a pyrazolo[1,5-a]pyridine scaffold.
• To investigate the G-protein coupling bias (Gα(o) vs. Gα(i)) of these compounds at D2 receptors.
• To evaluate the potential of these compounds to improve negative symptoms of schizophrenia through selective D2R activation.

Main Methods:

• Synthesis of pyrazolo[1,5-a]pyridine derivatives as dopamine surrogates.
• Binding affinity assays (K(i)) for D(2L), D(2S), and D3 receptors.
• G-protein activation assays using [(35)S]GTPγS incorporation to measure Gα(o1) and Gα(i2) coupling.
• Assessment of β-arrestin-2 recruitment to evaluate ligand bias.

Main Results:

• Several synthesized compounds exhibited low- to subnanomolar binding affinities for D2 and D3 receptors.
• Compounds demonstrated a significant bias towards promoting Gα(o1) coupling over Gα(i2) at D2S receptors.
• Carbaldoxime 8b showed striking functional selectivity, with potent Gα(o1) activation and weaker Gα(i2) activation.
• 1,4-disubstituted aromatic piperazines acted as antagonists for β-arrestin-2 recruitment, indicating G-protein bias.

Conclusions:

• Novel pyrazolo[1,5-a]pyridine derivatives display functional selectivity at dopamine D2 receptors, favoring Gα(o) over Gα(i) signaling.
• This G-protein bias suggests potential therapeutic utility for treating negative symptoms of schizophrenia.
• Ligand efficacy and selectivity are influenced by the chemical structure and functional groups of the pyrazolo[1,5-a]pyridine moiety.